Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Assets: 2016-2024

Historic Assets for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $285.7 million.

  • UroGen Pharma's Assets fell 38.71% to $185.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.0 million, marking a year-over-year decrease of 38.71%. This contributed to the annual value of $285.7 million for FY2024, which is 60.23% up from last year.
  • Latest data reveals that UroGen Pharma reported Assets of $285.7 million as of FY2024, which was up 60.23% from $178.3 million recorded in FY2023.
  • UroGen Pharma's 5-year Assets high stood at $285.7 million for FY2024, and its period low was $119.7 million during FY2021.
  • For the 3-year period, UroGen Pharma's Assets averaged around $199.9 million, with its median value being $178.3 million (2023).
  • Its Assets has fluctuated over the past 5 years, first crashed by 39.72% in 2020, then surged by 60.23% in 2024.
  • Over the past 5 years, UroGen Pharma's Assets (Yearly) stood at $122.0 million in 2020, then dropped by 1.85% to $119.7 million in 2021, then climbed by 13.26% to $135.6 million in 2022, then surged by 31.48% to $178.3 million in 2023, then skyrocketed by 60.23% to $285.7 million in 2024.